Posts Tagged ‘GLP-1 agonists’

Cancer might not be top of mind when most people think about the complications of obesity. But at least 13 different cancers have a clear association with obesity. A new study published Friday in JAMA Network Open examines the risk of these cancers in patients with type 2 diabetes and obesity. The primary objective was […]

It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]

New research at the annual Endocrine Society meeting in Boston suggests that semaglutide treatment may work in part through enhancement of taste sensitivity in persons with obesity – especially sensitivity to the sweetness of foods. Mojca Jensterle Sever presented the results. She explained: “Some studies have reported that individuals living with obesity often perceive tastes […]

Perhaps the most persistent fault that people find with new obesity medicines is the need to keep taking them forever. “Nobody is ready ” for that, says Business Insider. “Patients hate forever drugs,” says the New York Times. And they have a point. Obesity medicine doctors are quick to say “suck it up.” That’s just […]

Clickbait is a new spin on an old thing. Sex, drugs, and rock ’n’ roll used to be the formula for drawing eyes to advertising. Now the hottest clickbait is sex, alcohol, and GLP-1 drugs. People magazine tells us this month that GLP-1 agonists “may impact the desire to drink alcohol or have sex.” Oh […]

It seems that people who are finding tremendous relief from obesity with GLP-1 medicines just won’t shut up about the benefits of turning down the volume on food noise. Nancy Barnes, one of these people, tells the PBS News Hour: “The noise in your head stops. It is just so unbelievable” Obesity medicine physician Melanie […]

Perhaps it was inevitable. Last week, the Times plunged into stereotypes about obesity care and gender, asking “Is the era of ‘Brozempic’ upon us?” The spark for the story comes from the efforts of telehealth businesses trying to crack the code for reaching men with concerns about obesity. It can be awkward. The cultural baggage […]

GLP-1 agonists offer an opportunity to reduce health disparities, writes Karen Kaplan in the Los Angeles Times. But a problem with equity in obesity care is getting in the way. So instead, it seems they may be making things worse. Cardiologist and health services researcher Lauren Eberly tells Kaplan: “These patients have a higher burden […]

In The Conversation this week, Emma Beckett tells us that drugs for treating obesity won’t cure it, “but they might make us more fat-phobic.” Her rationale is simple enough. All the buzz “plays into ideas of fat stigma and fat phobia.” No matter that doctors, scientists, and the FDA all say otherwise, she says these […]

A new economic analysis in JAMA Network Open brings unsurprising news: manufacturing costs for GLP-1 agonists are a tiny fraction of the price for these important medicines. This is always the case for innovative prescription drugs that must recover billions of dollars of development costs in order to be profitable. The response from policy makers […]